Succinic Acid

Succinic Acid

SCHEMBL507226

Clc1ccc2c(c1NCc1ccc3ccoc3c1)CCNCC2.O=C(O)CCC(=O)O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR2A known ✓ P28223 3/20 0.39
HTR2C known ✓ P28335 3/20 0.39
HTR1B known ✓ P28222 2/20 0.31
HTR2B P41595 3/20 0.39
FFAR1 O14842 2/20 0.35
ITGB2 P05107 10/20 0.34
ICAM1 P05362 10/20 0.34
ITGAL P20701 10/20 0.34
PDE5A O76074 1/20 0.31
CYP2C9 P11712 1/20 0.31
GLI1 P08151 1/20 0.31
AURKA O14965 1/20 0.30
RPS6KB1 P23443 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10228296 0.92 HTR2B (0.45) HTR2AHTR2CHTR2BPDE5AHTR1B
Succinic Acid SCHEMBL507210 0.85 FFAR1 (0.47) HTR2AHTR2CHTR2BFFAR1
Succinic Acid SCHEMBL507183 0.84 MEN1 (0.34) HTR2AHTR2CHTR2BFFAR1PDE5A
Succinic Acid SCHEMBL506304 0.82 FFAR1 (0.44) HTR2AHTR2CHTR2BFFAR1
Succinic Acid SCHEMBL10476124 0.82 HTR2A (0.41) HTR2AHTR2CHTR2BFFAR1PDE5A
Succinic Acid SCHEMBL506560 0.81 FFAR1 (0.35) HTR2AHTR2CHTR2BFFAR1PDE5A
Succinic Acid SCHEMBL10476196 0.81 FFAR1 (0.44) HTR2AHTR2CHTR2BFFAR1
Succinic Acid SCHEMBL508203 0.81 PDE5A (0.44) PDE5ACYP2C9
Succinic Acid SCHEMBL507160 0.81 FFAR1 (0.46) HTR2AHTR2CHTR2BFFAR1
Succinic Acid SCHEMBL10476256 0.81 KMT2A (0.41) HTR2AHTR2CHTR2BFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
EP-2479168-A1 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists ELI LILLY AND COMPANY (US) 2012-07-25 EP disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 HTR2A 4/4885HTR2C 1/4885HTR1B 9/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A HTR2A 4/4885HTR2C 1/4885HTR1B 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.